EMC易倍

Solving human diseases
Perfection of Helping Health
EMC易倍(中国区)体育官方网站
Focusing on innovative anti-tumor immune precision therapy, benefiting China and enjoying international reputation
EMC易倍(中国区)体育官方网站

About Carbiogene


Zhejiang Carbiogene Therapeutics Co., Ltd. (Carbiogene) is a key enterprise co-founded by renowned scientists from home and abroad and introduced through government initiatives. It is recognized as a National High-Tech Enterprise, a China Future Unicorn Enterprise, and a Zhejiang Provincial Specialized, Refined, Distinctive and Innovative (SRDI) Enterprise , as well as a Hangzhou Key Enterprise Slated for IPO. It is a high-tech biopharmaceutical innovation enterprise integrating R&D, manufacturing, and sales.

Carbiogene's R&D and manufacturing center is built to AABB standards and is equipped with GMP-compliant facilities, having obtained ISO three-system certification certifications. The Company possesses an international innovative drug technology platform centered on novel anti-tumor immunotherapeutic products (next-generation CAR-T, in vivo CAR-T, etc.), with CAR technology and the globally pioneering scalable high-purity retrovirus vector technology as its core. Its product portfolio covers hematologic malignancies, solid tumors, and autoimmune diseases, with a focus on the R&D, clinical application, and industrialization of cell and gene therapy technologies.

Since its establishment, the company has maintained steady industrial growth with remarkable achievements. It has been honored with numerous accolades, including National High-Tech Enterprise, China Future Unicorn Enterprise, Zhejiang Provincial Specialized, Refined, Distinctive and Innovative (SRDI) Enterprise, Hangzhou Key Enterprise Slated for IPO, Zhejiang Provincial Enterprise Research Institute, Zhejiang Provincial High-Tech Enterprise R&D Center, Zhejiang Province High-Growth Technology Enterprise, Hangzhou Expert Workstation, Overseas High-Level Talent Innovation and Entrepreneurship Enterprise, Top 50 Most Investment-Valuable Enterprises in China's Healthcare Industry, Most Influential Brand of Zhejiang Business Awards, Rising Star Enterprise in the In Vivo Cell Therapy, and Top 10 Promising Hangzhou Overseas Returnee-founded Enterprises. The company has received substantial funding support from major national, provincial, and municipal science and technology programs. It holds more than 150 independent intellectual property assets, including invention patents, utility model patents, and software copyrights, and has been certified under the National Enterprise Intellectual Property Management System.

In addition, the company operates a Medical Laboratory Center and an AI-Powered Digital Intelligent Healthcare Center as complementary facilities, forming a closed-loop industrial ecosystem and striving to become a globally leading, CGT-focused innovative biotechnology enterprise.

[MORE]

EMC易倍(中国区)体育官方网站

News

【网站地图】